NCT06384131View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

May 14, 2025

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABI-4334

10 mg or 50 mg tablets for oral administration

DRUG

Placebo

10 mg or 50 mg tablets for oral administration

Trial Locations (2)

Unknown

ARENSIA Exploratory Medicine Chisinau, Chisinau

New Zealand Clinical Research, Auckland

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT06384131 - A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection | Biotech Hunter | Biotech Hunter